Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’...
Transcript of Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’...
![Page 1: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/1.jpg)
"Manufacturing challenges - now and future - how will we ensure patient access to these medicines?" Bo Kara, Cell Gene Therapy: Process
Development
Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy Products
![Page 2: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/2.jpg)
Generic process for genetic modification of autologous T cells
EMA CAT Workshop London November 2016
QP Release
![Page 3: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/3.jpg)
Manufacturing Models: T- Cell Processing – Current? Centralised
EMA CAT Workshop London November 2016
• Single product or single platform
• Lower CoG
• Product and process knowledge in one place
• Easier validation
• No tech transfers to other sites
• No duplication of QC across multiple sites
• Reduced ‘cost of testing’?
• Requires cryo in/out of facility
• Long(er), more variable distribution chain
• Security of ‘treatment’ supply’ if facility
issues?
![Page 4: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/4.jpg)
Autologous T-cell product manufacturing
– Heterogeneity - starting materials – Manual steps, operator dependent, labour intensive – Need: highly qualified operators – Lack of automation and functionally closed manufacturing
systems – Scale-out: limited
– Availability of adequate facilities and highly trained operators
– Centralised manufacturing: leukapheresis material/cellular product shipping – potential risks for the cell product?
EMA CAT Workshop London November 2016
![Page 5: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/5.jpg)
Current - Manufacturing Logistics
EMA CAT Workshop London November 2016
QP Release
![Page 6: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/6.jpg)
Centralised Manufacturing: Logistics
EMA CAT Workshop London November 2016
– Shipping: potential risks? – Leukapheresis material and final cellular product –
– Short shelf-life (can have) or, – Critical delivery times - manufacturing timescales or patient conditioning regimens
– International borders – Bottleneck and source of potential risk – Inconsistencies in service levels for pharmaceutical products – Approach to security are a source of complication in logistics planning – Loss of shipments?
– Cryopreserved cell products? – Shipped on dry ice – Hospital receiving the cell product:
– Handling frozen cell material and consistency? – Thawing process and consistency?
![Page 7: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/7.jpg)
Meeting the demand/need: future – example
– Huge potential: 350 clinical studies studying the use of cell-based therapies in a number of haematological and solid tumours (clinicaltrials.gov accessed Sept 27 2016)
– Initial data confined to a subset of less common tumours (Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia and Diffuse and large B cell lymphoma): – Total incidence is ~60,000 patients per year in the US and a similar incidence in the
EU5 (UK, Germany, France, Italy and Spain)
– Commercialisation: What is the manufacturing model that ensures access to these medicines?
– As we work to extend cell-based therapies into solid tumours: – Potential population becomes significantly larger – non-small cell lung cancer
alone affects nearly 200,000 individuals per year – Commercialisation: What is the manufacturing model that ensures access to
these medicines?
EMA CAT Workshop London November 2016
![Page 8: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/8.jpg)
Manufacturing Models: Cell Processing Decentralised?
EMA CAT Workshop London November 2016
• Shorter distribution chain
• Improved patient access to treatment
• Can align with local practises and needs
• Security of ‘treatment’ supply if one site has issues
• Could handle shorter shelf products
• Multiple capital investment
• Additional TT and validation time/costs
• RM/consumables supply chain
• Ensuring ‘same’ product across sites?
• QC replication: cost of testing
• Quality oversight replication
De-centralised?
![Page 9: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/9.jpg)
Manufacturing Models: Cell Processing ‘Localised’
EMA CAT Workshop London November 2016
Localised/in-hospital: innovation required
PAT: Support
RTR
QbD: process, analytics,
automation
Regulatory?
QP Release?
Supply Chain:
Vector, Flow path, Other
Materials Automation Process? Analytics? Equipment consistency?
![Page 10: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/10.jpg)
Discussion topics
– Localised manufacturing: – Regulatory framework? – GMP manufacturing – how do we bring into localised manufacturing? – Can we see new ‘bottlenecks’?
– E.g. 100,000’s of patient batches – will QP’s be able to meet demand? – Other?
EMA CAT Workshop London November 2016
![Page 11: Manufacturing ensure patient access · • RM/consumables supply chain • Ensuring ‘same’ product across sites? • QC replication: cost of testing • Quality oversight replication](https://reader034.fdocuments.us/reader034/viewer/2022042017/5e75139827238523447b8143/html5/thumbnails/11.jpg)
EMA CAT Workshop London November 2016
On a mission to make a difference If we do these things well, we will do better by patients, our shareholders and society. And we will fulfil our mission: to help people do more, feel better, live longer.